Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENCEPT 10/11-28 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Female contraception
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol: primarily CYP3A4; Levonorgestrel: CYP3A4, undergoes reduction and sulfation.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
98% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Volume of distribution is approximately 0.8-1.0 L/kg, indicating extensive tissue distribution.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral bioavailability is approximately 90%, with minimal first-pass metabolism.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for mild to moderate renal impairment. In severe renal impairment (GFR <30 m L/min), use with caution due to potential fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in patients with Child-Pugh class B or C hepatic impairment (moderate to severe). In mild hepatic impairment (Child-Pugh class A), use with caution due to altered hormone metabolism.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not indicated for use in pediatric patients before menarche. For post-menarche adolescents, follow same dosing as adults.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for use in women above 55 years of age due to increased risk of thromboembolic events and lack of efficacy data.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI),Visual abnormalities (retinal thrombosis, papilledema),Hepatic neoplasia (benign/malignant liver tumors),Hypertension,Glucose intolerance/diabetes,Gallbladder disease,Depression,Bleeding irregularities
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No specific food interactions are known. However, grapefruit juice may increase ethinyl estradiol levels; consider limiting grapefruit juice intake. Avoid excessive alcohol, as it may increase liver toxicity risk.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
GENCEPT 10/11-28 contains gestodene and ethinylestradiol. Gestodene is a progestogen; ethinylestradiol is an estrogen. Combined hormonal contraceptives are contraindicated in pregnancy. First trimester: no increased risk of major birth defects based on epidemiological studies, but should not be used once pregnancy is confirmed. Second and third trimesters: no therapeutic indication; animal studies show fetotoxicity at high doses. Overall, use is not recommended in pregnancy.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Gestodene and ethinylestradiol are excreted in breast milk in small amounts. The M/P ratio for ethinylestradiol is approximately 0.02; for gestodene, it is unknown but likely low. Combined hormonal contraceptives may reduce milk production and composition, especially in early lactation; use is generally not recommended during breastfeeding, particularly in the first 6 months postpartum. Progestin-only alternatives are preferred.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dose adjustment is applicable as the drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) would theoretically reduce ethinylestradiol and gestodene levels, but since the drug is not used in pregnancy, no dosing recommendations are made.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
GENCEPT 10/11-28 is a combination oral contraceptive containing ethinyl estradiol 10 mcg and drospirenone 3 mg (24 active tablets) plus placebo (4 tablets). It is used for contraception and treatment of moderate acne vulgaris in women who desire oral contraception. The 24-day active regimen increases ovarian suppression and reduces breakthrough bleeding. Drospirenone has antimineralocorticoid activity, which may cause hyperkalemia in patients with renal impairment, hepatic disease, or adrenal insufficiency. Monitor potassium in at-risk patients. Do not use with other potassium-sparing drugs. Avoid in women with hypertension, diabetes with vascular disease, or migraine with aura due to increased cardiovascular risk with low-dose EE. Consider starting on first day of menses for immediate contraceptive effect.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one pill daily at the same time, in the order shown on the pack. Do not skip pills.,Use backup contraception (e.g., condoms) if you miss a pill, vomit within 3-4 hours after taking a pill, or have severe diarrhea.,Contact your doctor immediately if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Cigarette smoking increases the risk of serious cardiovascular side effects. Do not smoke while taking this medication.,Store at room temperature, away from moisture and heat.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENCEPT 10/11-28 vs ALTAVERA, answered by our medical review team.
GENCEPT 10/11-28 is a Oral Contraceptive that works by Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENCEPT 10/11-28 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENCEPT 10/11-28 is: One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENCEPT 10/11-28 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENCEPT 10/11-28 is classified as Category C. GENCEPT 10/11-28 contains gestodene and ethinylestradiol. Gestodene is a progestogen; ethinylestradiol is an estrogen. Combined hormonal contraceptives are contraindicated in pregn. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.